Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02121899 · ClinicalTrials.gov registry record
Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Terminated
- Registry status
- 44
- Enrollment target
NCT02121899: Clinical Trial study, sponsored by Myriad Genetic Laboratories.
NCT02121899 is a clinical trial that was terminated before completion, run by Myriad Genetic Laboratories. The registered enrollment target is 44 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02121899 was terminated before completion, sponsored by Myriad Genetic Laboratories.
- TERMINATED
- Registry status
- 44 participants
- Enrollment target
Study Summary
This registry is intended to measure the effect of myPlan Lung Cancer™ test has on influencing treatment decisions of Oncologists when added to standard clinical-pathological parameters in patients with early stage NSCLC. The sponsor is conducting two parallel registries, with one directed at Surgeons (ONC003) and the other at Oncologists (ONC006). This registry is specific to Oncologists (ONC006).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02121899
The ClinicalTrials.gov registry entry for NCT02121899 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Myriad Genetic Laboratories, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02121899 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02121899 about?
NCT02121899 is a clinical study titled "Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)". This registry is intended to measure the effect of myPlan Lung Cancer™ test has on influencing treatment decisions of Oncologists when added to standard clinical-pathological parameters in patients with early stage NSCLC. The sponsor is conducting two parallel registries, with one directed at Surge...
What is the current status of trial NCT02121899?
This trial is currently terminated. The enrollment target is 44 participants. The study started on 2015-04. Estimated completion is 2017-07-31.
Who is sponsoring clinical trial NCT02121899?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.